Oxana Polyakova

发表

Identification of Novel Interacting Partners of Sirtuin6

R. Grimley, J. Vamathevan, R. Solari, 2012, PloS one.

Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation

David M. Wilson, G. Drewes, D. Eberhard, 2015, Nature chemical biology.

Discovery of Novel Irreversible Inhibitors of Interleukin (IL)-2-inducible Tyrosine Kinase (Itk) by Targeting Cysteine 442 in the ATP Pocket

R. Grimley, R. Solari, J. Harling, 2013, The Journal of Biological Chemistry.

Both Ca2+ and Zn2+ are essential for S100A12 protein oligomerization and function

D. Foell, I. Lednev, A. Ianoul, 2009, BMC Biochemistry.

Design and development of a series of borocycles as selective, covalent kallikrein 5 inhibitors.

A. Hovnanian, J. Liddle, P. Thomas, 2019, Bioorganic & medicinal chemistry letters.

Misfolded forms of glyceraldehyde‐3‐phosphate dehydrogenase interact with GroEL and inhibit chaperonin‐assisted folding of the wild‐type enzyme

V. Muronetz, G. Branlant, O. Roitel, 2005, Protein science : a publication of the Protein Society.

Over Expression of Wild Type or a Catalytically Dead Mutant of SIRTUIN 6 Does Not Influence NFκB Responses

R. Grimley, C. Chung, J. Vamathevan, 2012, PloS one.

Evaluation of a crystallographic surrogate for kallikrein 5 in the discovery of novel inhibitors for Netherton syndrome.

A. Hovnanian, J. Liddle, Kathrine J. Smith, 2019, Acta crystallographica. Section F, Structural biology communications.

The γδTCR combines innate immunity with adaptive immunity by utilizing spatially distinct regions for agonist selection and antigen responsiveness

Paul A Bates, Natalie A. Roberts, Raphael A. G. Chaleil, 2018, Nature Immunology.

The γδTCR combines innate immunity with adaptive immunity by utilizing spatially distinct regions for agonist selection and antigen responsiveness

Natalie A. Roberts, Raphael A. G. Chaleil, P. Bates, 2018, Nature Immunology.

Proteolysis of prion protein by cathepsin S generates a soluble β-structured intermediate oligomeric form, with potential implications for neurotoxic mechanisms

P. Bayley, G. Dodson, I. Bronstein, 2009, European Biophysics Journal.

Kallikrein 5 inhibitors identified through structure based drug design in search for a treatment for Netherton Syndrome.

A. Hovnanian, J. Liddle, Kathrine J. Smith, 2019, Bioorganic & medicinal chemistry letters.